Robert F Siliciano

List of Publications by Year in Descending Order

187 papers	27,811 citations	89 h-index	166 g-index
210 ext. papers	32,080 ext. citations	16.6 avg, IF	6.93 L-index

#	Paper	IF	Citations
187	TCR-mimic bispecific antibodies to target the HIV-1 reservoir.. *Proceedings of the National Academy of Sciences of the United States of America*, **2022**, 119, e2123406119	11.5	0
186	Therapeutic efficacy of an Ad26/MVA vaccine with SIV gp140 protein and vesatolimod in ART-suppressed rhesus macaques.. *Npj Vaccines*, **2022**, 7, 53	9.5	0
185	A Possible Sterilizing Cure of HIV-1 Infection Without Stem Cell Transplantation. *Annals of Internal Medicine*, **2021**,	8	3
184	Similar Frequency and Inducibility of Intact Human Immunodeficiency Virus-1 Proviruses in Blood and Lymph Nodes. *Journal of Infectious Diseases*, **2021**, 224, 258-268	7	5
183	Impact of Anti-PD-1 and Anti-CTLA-4 on the Human Immunodeficiency Virus (HIV) Reservoir in People Living With HIV With Cancer on Antiretroviral Therapy: The AIDS Malignancy Consortium 095 Study. *Clinical Infectious Diseases*, **2021**, 73, e1973-e1981	11.6	11
182	Persistence of viral RNA in lymph nodes in ART-suppressed SIV/SHIV-infected Rhesus Macaques. *Nature Communications*, **2021**, 12, 1474	17.4	7
181	Nonstructured Treatment Interruptions Are Associated With Higher Human Immunodeficiency Virus Reservoir Size Measured by Intact Proviral DNA Assay in People Who Inject Drugs. *Journal of Infectious Diseases*, **2021**, 223, 1905-1913	7	4
180	Low Inducibility of Latent Human Immunodeficiency Virus Type 1 Proviruses as a Major Barrier to Cure. *Journal of Infectious Diseases*, **2021**, 223, 13-21	7	8
179	Antigen-driven clonal selection shapes the persistence of HIV-1-infected CD4+ T cells in vivo. *Journal of Clinical Investigation*, **2021**, 131,	15.9	29
178	Sequence Evaluation and Comparative Analysis of Novel Assays for Intact Proviral HIV-1 DNA. *Journal of Virology*, **2021**, 95,	6.6	11
177	Heightened resistance to host type 1 interferons characterizes HIV-1 at transmission and after antiretroviral therapy interruption. *Science Translational Medicine*, **2021**, 13,	17.5	14
176	HSF1 inhibition attenuates HIV-1 latency reversal mediated by several candidate LRAs In Vitro and Ex Vivo. *Proceedings of the National Academy of Sciences of the United States of America*, **2020**, 117, 15763-15771	11.5	10
175	Different human resting memory CD4 T cell subsets show similar low inducibility of latent HIV-1 proviruses. *Science Translational Medicine*, **2020**, 12,	17.5	38
174	Simian-Human Immunodeficiency Virus SHIV.C.CH505 Persistence in ART-Suppressed Infant Macaques Is Characterized by Elevated SHIV RNA in the Gut and a High Abundance of Intact SHIV DNA in Naive CD4 T Cells. *Journal of Virology*, **2020**, 95,	6.6	11
173	Differential decay of intact and defective proviral DNA in HIV-1-infected individuals on suppressive antiretroviral therapy. *JCI Insight*, **2020**, 5,	9.9	53
172	Longitudinal study reveals HIV-1-infected CD4+ T cell dynamics during long-term antiretroviral therapy. *Journal of Clinical Investigation*, **2020**, 130, 3543-3559	15.9	28
171	Nonsuppressible HIV-1 viremia: a reflection of how the reservoir persists. *Journal of Clinical Investigation*, **2020**, 130, 5665-5667	15.9	6

170	Multiple genetic programs contribute to CD4 T cell memory differentiation and longevity by maintaining T cell quiescence. *Cellular Immunology*, **2020**, 357, 104210	4.4	3
169	Intact proviral DNA assay analysis of large cohorts of people with HIV provides a benchmark for the frequency and composition of persistent proviral DNA. *Proceedings of the National Academy of Sciences of the United States of America*, **2020**, 117, 18692-18700	11.5	24
168	Autologous IgG antibodies block outgrowth of a substantial but variable fraction of viruses in the latent reservoir for HIV-1. *Proceedings of the National Academy of Sciences of the United States of America*, **2020**, 117, 32066-32077	11.5	11
167	Allogeneic bone marrow transplantation with post-transplant cyclophosphamide for patients with HIV and haematological malignancies: a feasibility study. *Lancet HIV,the*, **2020**, 7, e602-e610	7.8	6
166	Shared Mechanisms Govern HIV Transcriptional Suppression in Circulating CD103 and Gut CD4 T Cells. *Journal of Virology*, **2020**, 95,	6.6	2
165	Distinct viral reservoirs in individuals with spontaneous control of HIV-1. *Nature*, **2020**, 585, 261-267	50.4	97
164	Recommendations for measuring HIV reservoir size in cure-directed clinical trials. *Nature Medicine*, **2020**, 26, 1339-1350	50.5	43
163	A quantitative approach for measuring the reservoir of latent HIV-1 proviruses. *Nature*, **2019**, 566, 120-125	50.4	227
162	The Landscape of Persistent Viral Genomes in ART-Treated SIV, SHIV, and HIV-2 Infections. *Cell Host and Microbe*, **2019**, 26, 73-85.e4	23.4	38
161	Incentives for Viral Suppression in People Living with HIV: A Randomized Clinical Trial. *AIDS and Behavior*, **2019**, 23, 2337-2346	4.3	19
160	Assays to Measure Latency, Reservoirs, and Reactivation. *Current Topics in Microbiology and Immunology*, **2018**, 417, 23-41	3.3	18
159	Expanded cellular clones carrying replication-competent HIV-1 persist, wax, and wane. *Proceedings of the National Academy of Sciences of the United States of America*, **2018**, 115, E2575-E2584	11.5	131
158	Measuring replication competent HIV-1: advances and challenges in defining the latent reservoir. *Retrovirology*, **2018**, 15, 21	3.6	38
157	CMPK2 and BCL-G are associated with type 1 interferon-induced HIV restriction in humans. *Science Advances*, **2018**, 4, eaat0843	14.3	30
156	Insight into treatment of HIV infection from viral dynamics models. *Immunological Reviews*, **2018**, 285, 9-25	11.3	33
155	Cross-reactive microbial peptides can modulate HIV-specific CD8+ T cell responses. *PLoS ONE*, **2018** , 13, e0192098	3.7	7
154	The role of CD32 during HIV-1 infection. *Nature*, **2018**, 561, E17-E19	50.4	30
153	Latent HIV reservoirs exhibit inherent resistance to elimination by CD8+ T cells. *Journal of Clinical Investigation*, **2018**, 128, 876-889	15.9	104

152	HIV-1 latent reservoir size and diversity are stable following brief treatment interruption. *Journal of Clinical Investigation*, **2018**, 128, 3102-3115	15.9	56
151	Targeting the Latent Reservoir for HIV-1. *Immunity*, **2018**, 48, 872-895	32.3	166
150	Defective HIV-1 Proviruses Are Expressed and Can Be Recognized by Cytotoxic T Lymphocytes, which Shape the Proviral Landscape. *Cell Host and Microbe*, **2017**, 21, 494-506.e4	23.4	176
149	Proliferation of latently infected CD4 T cells carrying replication-competent HIV-1: Potential role in latent reservoir dynamics. *Journal of Experimental Medicine*, **2017**, 214, 959-972	16.6	228
148	Nuclear landscape of HIV-1 infection and integration. *Nature Reviews Microbiology*, **2017**, 15, 69-82	22.2	71
147	Transcriptional Reprogramming during Effector-to-Memory Transition Renders CD4 T Cells Permissive for Latent HIV-1 Infection. *Immunity*, **2017**, 47, 766-775.e3	32.3	92
146	Reactivation of simian immunodeficiency virus reservoirs in the brain of virally suppressed macaques. *Aids*, **2017**, 31, 5-14	3.5	87
145	Re-evaluating evolution in the HIV reservoir. *Nature*, **2017**, 551, E6-E9	50.4	51
144	Rapamycin-mediated mTOR inhibition uncouples HIV-1 latency reversal from cytokine-associated toxicity. *Journal of Clinical Investigation*, **2017**, 127, 651-656	15.9	45
143	HIV persistence: clonal expansion of cells in the latent reservoir. *Journal of Clinical Investigation*, **2017**, 127, 2536-2538	15.9	15
142	HIV-1 persistence following extremely early initiation of antiretroviral therapy (ART) during acute HIV-1 infection: An observational study. *PLoS Medicine*, **2017**, 14, e1002417	11.6	122
141	Reduced Frequency of Cells Latently Infected With Replication-Competent Human Immunodeficiency Virus-1 in Virally Suppressed Individuals Living in Rakai, Uganda. *Clinical Infectious Diseases*, **2017**, 65, 1308-1315	11.6	14
140	Reservoir expansion by T-cell proliferation may be another barrier to curing HIV infection. *Proceedings of the National Academy of Sciences of the United States of America*, **2016**, 113, 1692-4	11.5	23
139	Progress Toward HIV Eradication: Case Reports, Current Efforts, and the Challenges Associated with Cure. *Annual Review of Medicine*, **2016**, 67, 215-28	17.4	61
138	HIV Integration Site Analysis of Cellular Models of HIV Latency with a Probe-Enriched Next-Generation Sequencing Assay. *Journal of Virology*, **2016**, 90, 4511-4519	6.6	35
137	HIV reservoirs: what, where and how to target them. *Nature Reviews Microbiology*, **2016**, 14, 55-60	22.2	176
136	Real-Time Predictions of Reservoir Size and Rebound Time during Antiretroviral Therapy Interruption Trials for HIV. *PLoS Pathogens*, **2016**, 12, e1005535	7.6	67
135	Insufficient Evidence for Rare Activation of Latent HIV in the Absence of Reservoir-Reducing Interventions. *PLoS Pathogens*, **2016**, 12, e1005679	7.6	15

134	Evaluating Clonal Expansion of HIV-Infected Cells: Optimization of PCR Strategies to Predict Clonality. *PLoS Pathogens*, **2016**, 12, e1005689	7.6	42
133	Diverse fates of uracilated HIV-1 DNA during infection of myeloid lineage cells. *ELife*, **2016**, 5,	8.9	30
132	Measuring the Frequency of Latent HIV-1 in Resting CD4+ T Cells Using a Limiting Dilution Coculture Assay. *Methods in Molecular Biology*, **2016**, 1354, 239-53	1.4	61
131	Quantitative evaluation of the antiretroviral efficacy of dolutegravir. *JCI Insight*, **2016**, 1, e90033	9.9	12
130	Recent developments in the effort to cure HIV infection: going beyond N = 1. *Journal of Clinical Investigation*, **2016**, 126, 409-14	15.9	51
129	The Latent Reservoir for HIV-1: How Immunologic Memory and Clonal Expansion Contribute to HIV-1 Persistence. *Journal of Immunology*, **2016**, 197, 407-17	5.3	96
128	The mTOR Complex Controls HIV Latency. *Cell Host and Microbe*, **2016**, 20, 785-797	23.4	115
127	Defective proviruses rapidly accumulate during acute HIV-1 infection. *Nature Medicine*, **2016**, 22, 1043-9	50.5	413
126	Potent Inhibitors Active against HIV Reverse Transcriptase with K101P, a Mutation Conferring Rilpivirine Resistance. *ACS Medicinal Chemistry Letters*, **2015**, 6, 1075-9	4.3	19
125	Stoichiometric parameters of HIV-1 entry. *Virology*, **2015**, 474, 1-9	3.6	4
124	Towards an HIV-1 cure: measuring the latent reservoir. *Trends in Microbiology*, **2015**, 23, 192-203	12.4	152
123	Designing and Interpreting Limiting Dilution Assays: General Principles and Applications to the Latent Reservoir for Human Immunodeficiency Virus-1. *Open Forum Infectious Diseases*, **2015**, 2, ofv123	1	91
122	Reply: To PMID 25117799. *Journal of Allergy and Clinical Immunology*, **2015**, 136, 214	11.5	
121	Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations. *Nature* , **2015**, 517, 381-5	50.4	377
120	HIV-1 integration landscape during latent and active infection. *Cell*, **2015**, 160, 420-32	56.2	289
119	Ex vivo analysis identifies effective HIV-1 latency-reversing drug combinations. *Journal of Clinical Investigation*, **2015**, 125, 1901-12	15.9	275
118	New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo. *Nature Medicine*, **2014**, 20, 425-9	50.5	364
117	HIV: Not-so-innocent bystanders. *Nature*, **2014**, 505, 492-3	50.4	14

116	A primary CD4(+) T cell model of HIV-1 latency established after activation through the T cell receptor and subsequent return to quiescence. *Nature Protocols*, **2014**, 9, 2755-70	18.8	35
115	AIDS/HIV. Rekindled HIV infection. *Science*, **2014**, 345, 1005-6	33.3	12
114	HIV: Early treatment may not be early enough. *Nature*, **2014**, 512, 35-6	50.4	19
113	A mechanistic theory to explain the efficacy of antiretroviral therapy. *Nature Reviews Microbiology*, **2014**, 12, 772-80	22.2	50
112	Recent developments in the search for a cure for HIV-1 infection: targeting the latent reservoir for HIV-1. *Journal of Allergy and Clinical Immunology*, **2014**, 134, 12-9	11.5	63
111	Predicting the outcomes of treatment to eradicate the latent reservoir for HIV-1. *Proceedings of the National Academy of Sciences of the United States of America*, **2014**, 111, 13475-80	11.5	195
110	Screening for noise in gene expression identifies drug synergies. *Science*, **2014**, 344, 1392-6	33.3	142
109	Measuring reversal of HIV-1 latency ex vivo using cells from infected individuals. *Proceedings of the National Academy of Sciences of the United States of America*, **2014**, 111, 6860-1	11.5	7
108	HIV Prevention and Treatment Fields Join Forces. *EBioMedicine*, **2014**, 1, 4-5	8.8	2
107	Finding a cure for human immunodeficiency virus-1 infection. *Infectious Disease Clinics of North America*, **2014**, 28, 633-50	6.5	21
106	A pilot study assessing the safety and latency-reversing activity of disulfiram in HIV-1-infected adults on antiretroviral therapy. *Clinical Infectious Diseases*, **2014**, 58, 883-90	11.6	142
105	HLA-B*57 elite suppressor and chronic progressor HIV-1 isolates replicate vigorously and cause CD4+ T cell depletion in humanized BLT mice. *Journal of Virology*, **2014**, 88, 3340-52	6.6	36
104	CD4+ and CD8+ T cell activation are associated with HIV DNA in resting CD4+ T cells. *PLoS ONE*, **2014**, 9, e110731	3.7	72
103	Making sense of HIV innate sensing. *Immunity*, **2013**, 39, 998-1000	32.3	2
102	Recent trends in HIV-1 drug resistance. *Current Opinion in Virology*, **2013**, 3, 487-94	7.5	36
101	Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. *Cell*, **2013**, 155, 540-51	56.2	898
100	HIV latency and integration site placement in five cell-based models. *Retrovirology*, **2013**, 10, 90	3.6	85
99	Increasing extracellular protein concentration reduces intracellular antiretroviral drug concentration and antiviral effect. *AIDS Research and Human Retroviruses*, **2013**, 29, 1434-42	1.6	9

98	Targeting HIV latency: pharmacologic strategies toward eradication. *Drug Discovery Today*, **2013**, 18, 541-51	8.8	115
97	A novel PCR assay for quantification of HIV-1 RNA. *Journal of Virology*, **2013**, 87, 6521-5	6.6	64
96	From reactivation of latent HIV-1 to elimination of the latent reservoir: the presence of multiple barriers to viral eradication. *BioEssays*, **2013**, 35, 544-52	4.1	62
95	Challenges in detecting HIV persistence during potentially curative interventions: a study of the Berlin patient. *PLoS Pathogens*, **2013**, 9, e1003347	7.6	196
94	An in-depth comparison of latent HIV-1 reactivation in multiple cell model systems and resting CD4+ T cells from aviremic patients. *PLoS Pathogens*, **2013**, 9, e1003834	7.6	283
93	Comparative analysis of measures of viral reservoirs in HIV-1 eradication studies. *PLoS Pathogens*, **2013**, 9, e1003174	7.6	422
92	Rapid quantification of the latent reservoir for HIV-1 using a viral outgrowth assay. *PLoS Pathogens*, **2013**, 9, e1003398	7.6	183
91	BET bromodomain-targeting compounds reactivate HIV from latency via a Tat-independent mechanism. *Cell Cycle*, **2013**, 12, 452-62	4.7	169
90	HIV-1 eradication strategies: design and assessment. *Current Opinion in HIV and AIDS*, **2013**, 8, 318-25	4.2	52
89	Endothelial cell stimulation overcomes restriction and promotes productive and latent HIV-1 infection of resting CD4+ T cells. *Journal of Virology*, **2013**, 87, 9768-79	6.6	18
88	Multi-step inhibition explains HIV-1 protease inhibitor pharmacodynamics and resistance. *Journal of Clinical Investigation*, **2013**, 123, 3848-60	15.9	105
87	Redefining the viral reservoirs that prevent HIV-1 eradication. *Immunity*, **2012**, 37, 377-88	32.3	324
86	A quantitative basis for antiretroviral therapy for HIV-1 infection. *Nature Medicine*, **2012**, 18, 446-51	50.5	122
85	Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. *Immunity*, **2012**, 36, 491-501	32.3	570
84	Outwitting evolution: fighting drug-resistant TB, malaria, and HIV. *Cell*, **2012**, 148, 1271-83	56.2	123
83	Host factors dictate control of viral replication in two HIV-1 controller/chronic progressor transmission pairs. *Nature Communications*, **2012**, 3, 716	17.4	50
82	Developing strategies for HIV-1 eradication. *Trends in Immunology*, **2012**, 33, 554-62	14.4	77
81	HIV-1 DNA is detected in bone marrow populations containing CD4+ T cells but is not found in purified CD34+ hematopoietic progenitor cells in most patients on antiretroviral therapy. *Journal of Infectious Diseases*, **2012**, 205, 1014-8	7	79

80	Novel structurally related compounds reactivate latent HIV-1 in a bcl-2-transduced primary CD4+ T cell model without inducing global T cell activation. *Journal of Antimicrobial Chemotherapy*, **2012**, 67, 398-403	5.1	36
79	Antiretroviral dynamics determines HIV evolution and predicts therapy outcome. *Nature Medicine*, **2012**, 18, 1378-85	50.5	128
78	Measurement of antiviral activity in drugs for HIV-1. *Lancet Infectious Diseases, The*, **2011**, 11, 888-9	25.5	1
77	Prolonged control of replication-competent dual- tropic human immunodeficiency virus-1 following cessation of highly active antiretroviral therapy. *Retrovirology*, **2011**, 8, 97	3.6	43
76	A critical subset model provides a conceptual basis for the high antiviral activity of major HIV drugs. *Science Translational Medicine*, **2011**, 3, 91ra63	17.5	54
75	Disulfiram reactivates latent HIV-1 in a Bcl-2-transduced primary CD4+ T cell model without inducing global T cell activation. *Journal of Virology*, **2011**, 85, 6060-4	6.6	155
74	Influence of host gene transcription level and orientation on HIV-1 latency in a primary-cell model. *Journal of Virology*, **2011**, 85, 5384-93	6.6	95
73	HIV latency. *Cold Spring Harbor Perspectives in Medicine*, **2011**, 1, a007096	5.4	354
72	Short communication: dynamic constraints on the second phase compartment of HIV-infected cells. *AIDS Research and Human Retroviruses*, **2011**, 27, 759-61	1.6	19
71	No evidence for decay of the latent reservoir in HIV-1-infected patients receiving intensive enfuvirtide-containing antiretroviral therapy. *Journal of Infectious Diseases*, **2010**, 201, 293-6	7	59
70	Control of HIV-1 in elite suppressors despite ongoing replication and evolution in plasma virus. *Journal of Virology*, **2010**, 84, 7018-28	6.6	100
69	Evolution of the HIV-1 nef gene in HLA-B*57 positive elite suppressors. *Retrovirology*, **2010**, 7, 94	3.6	33
68	Biomarkers of HIV replication. *Current Opinion in HIV and AIDS*, **2010**, 5, 491-7	4.2	11
67	What do we need to do to cure HIV infection. *Topics in HIV Medicine: A Publication of the International AIDS Society, USA*, **2010**, 18, 104-8		14
66	Analysis of human immunodeficiency virus type 1 viremia and provirus in resting CD4+ T cells reveals a novel source of residual viremia in patients on antiretroviral therapy. *Journal of Virology*, **2009**, 83, 8470-81	6.6	108
65	Role of natural killer cells in a cohort of elite suppressors: low frequency of the protective KIR3DS1 allele and limited inhibition of human immunodeficiency virus type 1 replication in vitro. *Journal of Virology*, **2009**, 83, 5028-34	6.6	63
64	Isolation of a cellular factor that can reactivate latent HIV-1 without T cell activation. *Proceedings of the National Academy of Sciences of the United States of America*, **2009**, 106, 6321-6	11.5	38
63	A simian immunodeficiency virus-infected macaque model to study viral reservoirs that persist during highly active antiretroviral therapy. *Journal of Virology*, **2009**, 83, 9247-57	6.6	120

62	Small-molecule screening using a human primary cell model of HIV latency identifies compounds that reverse latency without cellular activation. *Journal of Clinical Investigation*, **2009**, 119, 3473-86	15.9	186
61	Constraints on the dominant mechanism for HIV viral dynamics in patients on raltegravir. *Antiviral Therapy*, **2009**, 14, 263-271	1.6	23
60	Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs. *Nature Medicine*, **2008**, 14, 762-6	50.5	249
59	Viral reservoirs, residual viremia, and the potential of highly active antiretroviral therapy to eradicate HIV infection. *Journal of Allergy and Clinical Immunology*, **2008**, 122, 22-8	11.5	154
58	Orientation-dependent regulation of integrated HIV-1 expression by host gene transcriptional readthrough. *Cell Host and Microbe*, **2008**, 4, 134-46	23.4	166
57	Chronic CD4+ T-cell activation and depletion in human immunodeficiency virus type 1 infection: type I interferon-mediated disruption of T-cell dynamics. *Journal of Virology*, **2008**, 82, 1870-83	6.6	135
56	The role of protective HCP5 and HLA-C associated polymorphisms in the control of HIV-1 replication in a subset of elite suppressors. *Aids*, **2008**, 22, 541-4	3.5	47
55	Preservation of FoxP3+ regulatory T cells in the peripheral blood of human immunodeficiency virus type 1-infected elite suppressors correlates with low CD4+ T-cell activation. *Journal of Virology*, **2008**, 82, 8307-15	6.6	107
54	Decay dynamics of HIV-1 depend on the inhibited stages of the viral life cycle. *Proceedings of the National Academy of Sciences of the United States of America*, **2008**, 105, 4832-7	11.5	105
53	Transmission of human immunodeficiency virus type 1 from a patient who developed AIDS to an elite suppressor. *Journal of Virology*, **2008**, 82, 7395-410	6.6	82
52	Experimental approaches to the study of HIV-1 latency. *Nature Reviews Microbiology*, **2007**, 5, 95-106	22.2	169
51	Isolation and characterization of replication-competent human immunodeficiency virus type 1 from a subset of elite suppressors. *Journal of Virology*, **2007**, 81, 2508-18	6.6	227
50	Limits on replenishment of the resting CD4+ T cell reservoir for HIV in patients on HAART. *PLoS Pathogens*, **2007**, 3, e122	7.6	57
49	The HBV drug entecavir - effects on HIV-1 replication and resistance. *New England Journal of Medicine*, **2007**, 356, 2614-21	59.2	231
48	Treatment implications of the latent reservoir for HIV-1. *Advances in Pharmacology*, **2007**, 55, 411-25	5.7	15
47	Stability of the latent reservoir for HIV-1 in patients receiving valproic acid. *Journal of Infectious Diseases*, **2007**, 195, 833-6	7	149
46	Nuclear retention of multiply spliced HIV-1 RNA in resting CD4+ T cells. *PLoS Pathogens*, **2006**, 2, e68	7.6	162
45	Residual human immunodeficiency virus type 1 viremia in some patients on antiretroviral therapy is dominated by a small number of invariant clones rarely found in circulating CD4+ T cells. *Journal of Virology*, **2006**, 80, 6441-57	6.6	321

44	Marked intraindividual variability in antiretroviral concentrations may limit the utility of therapeutic drug monitoring. *Clinical Infectious Diseases*, **2006**, 42, 1189-96	11.6	96
43	Maintenance of viral suppression in HIV-1-infected HLA-B*57+ elite suppressors despite CTL escape mutations. *Journal of Experimental Medicine*, **2006**, 203, 1357-69	16.6	221
42	Neutralizing antibodies do not mediate suppression of human immunodeficiency virus type 1 in elite suppressors or selection of plasma virus variants in patients on highly active antiretroviral therapy. *Journal of Virology*, **2006**, 80, 4758-70	6.6	136
41	HIV-1 viral load blips are of limited clinical significance. *Journal of Antimicrobial Chemotherapy*, **2006** , 57, 803-5	5.1	83
40	The latent reservoir for HIV-1 in resting CD4+ T cells and other viral reservoirs during chronic infection: insights from treatment and treatment-interruption trials. *Current Opinion in HIV and AIDS*, **2006**, 1, 62-8	4.2	26
39	The latent reservoir for HIV-1 in resting CD4+ T cells: a barrier to cure. *Current Opinion in HIV and AIDS*, **2006**, 1, 121-8	4.2	25
38	Enhanced culture assay for detection and quantitation of latently infected, resting CD4+ T-cells carrying replication-competent virus in HIV-1-infected individuals. *Methods in Molecular Biology*, **2005**, 304, 3-15	1.4	180
37	G-->A hypermutation in protease and reverse transcriptase regions of human immunodeficiency virus type 1 residing in resting CD4+ T cells in vivo. *Journal of Virology*, **2005**, 79, 1975-80	6.6	142
36	Kinetics of human immunodeficiency virus type 1 decay following entry into resting CD4+ T cells. *Journal of Virology*, **2005**, 79, 2199-210	6.6	163
35	Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART. *JAMA - Journal of the American Medical Association*, **2005**, 293, 817-29	27.4	281
34	Scientific rationale for antiretroviral therapy in 2005: viral reservoirs and resistance evolution. *Topics in HIV Medicine: A Publication of the International AIDS Society, USA*, **2005**, 13, 96-100		18
33	Genotypic analysis of HIV-1 drug resistance at the limit of detection: virus production without evolution in treated adults with undetectable HIV loads. *Journal of Infectious Diseases*, **2004**, 189, 1452-65	7	164
32	Genotypic resistance in HIV-1-infected patients with persistently detectable low-level viremia while receiving highly active antiretroviral therapy. *Clinical Infectious Diseases*, **2004**, 39, 1030-7	11.6	56
31	Analysis of human immunodeficiency virus type 1 transcriptional elongation in resting CD4+ T cells in vivo. *Journal of Virology*, **2004**, 78, 9105-14	6.6	114
30	A long-term latent reservoir for HIV-1: discovery and clinical implications. *Journal of Antimicrobial Chemotherapy*, **2004**, 54, 6-9	5.1	93
29	Continued production of drug-sensitive human immunodeficiency virus type 1 in children on combination antiretroviral therapy who have undetectable viral loads. *Journal of Virology*, **2004**, 78, 968-79	6.6	86
28	Mechanisms of HIV-1 escape from immune responses and antiretroviral drugs. *Current Opinion in Immunology*, **2004**, 16, 470-6	7.8	44
27	Novel single-cell-level phenotypic assay for residual drug susceptibility and reduced replication capacity of drug-resistant human immunodeficiency virus type 1. *Journal of Virology*, **2004**, 78, 1718-29	6.6	157

26	Resting CD4+ T cells from human immunodeficiency virus type 1 (HIV-1)-infected individuals carry integrated HIV-1 genomes within actively transcribed host genes. *Journal of Virology*, **2004**, 78, 6122-33	6.6	267
25	The multifactorial nature of HIV-1 latency. *Trends in Molecular Medicine*, **2004**, 10, 525-31	11.5	198
24	Analysis of human immunodeficiency virus type 1 gene expression in latently infected resting CD4+ T lymphocytes in vivo. *Journal of Virology*, **2003**, 77, 7383-92	6.6	143
23	Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. *Nature Medicine*, **2003**, 9, 727-8	50.5	1187
22	Resting CD4+ T lymphocytes but not thymocytes provide a latent viral reservoir in a simian immunodeficiency virus-Macaca nemestrina model of human immunodeficiency virus type 1-infected patients on highly active antiretroviral therapy. *Journal of Virology*, **2003**, 77, 4938-49	6.6	100
21	Latency in human immunodeficiency virus type 1 infection: no easy answers. *Journal of Virology*, **2003**, 77, 1659-65	6.6	143
20	Intrinsic stability of episomal circles formed during human immunodeficiency virus type 1 replication. *Journal of Virology*, **2002**, 76, 4138-44	6.6	156
19	Persistence of wild-type virus and lack of temporal structure in the latent reservoir for human immunodeficiency virus type 1 in pediatric patients with extensive antiretroviral exposure. *Journal of Virology*, **2002**, 76, 9481-92	6.6	110
18	Molecular characterization of preintegration latency in human immunodeficiency virus type 1 infection. *Journal of Virology*, **2002**, 76, 8518-31	6.6	202
17	The challenge of viral reservoirs in HIV-1 infection. *Annual Review of Medicine*, **2002**, 53, 557-93	17.4	500
16	The human immunodeficiency virus type 1 gag gene encodes an internal ribosome entry site. *Journal of Virology*, **2001**, 75, 181-91	6.6	128
15	Characterization of chemokine receptor utilization of viruses in the latent reservoir for human immunodeficiency virus type 1. *Journal of Virology*, **2000**, 74, 7824-33	6.6	129
14	Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy. *Annual Review of Immunology*, **2000**, 18, 665-708	34.7	438
13	A stable latent reservoir for HIV-1 in resting CD4(+) T lymphocytes in infected children. *Journal of Clinical Investigation*, **2000**, 105, 995-1003	15.9	124
12	Control of HIV despite the discontinuation of antiretroviral therapy. *New England Journal of Medicine*, **1999**, 340, 1683-4	59.2	272
11	Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. *Nature Medicine*, **1999**, 5, 512-7	50.5	1681
10	Reservoirs for HIV-1. *Current Infectious Disease Reports*, **1999**, 1, 298-304	3.9	6
9	Viral dynamics in HIV-1 infection. *Cell*, **1998**, 93, 665-71	56.2	176

8	Targeting of HIV-1 antigens for rapid intracellular degradation enhances cytotoxic T lymphocyte (CTL) recognition and the induction of de novo CTL responses in vivo after immunization. *Journal of Experimental Medicine*, **1997**, 185, 909-20	16.6	158
7	Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. *Science*, **1997**, 278, 1295-300	33.3	2379
6	Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. *Nature*, **1997**, 387, 183-8	50.4	1654
5	In vivo fate of HIV-1-infected T cells: quantitative analysis of the transition to stable latency. *Nature Medicine*, **1995**, 1, 1284-90	50.5	581
4	Transporter-independent processing of HIV-1 envelope protein for recognition by CD8+ T cells. *Nature*, **1993**, 364, 158-61	50.4	86
3	A soluble CD4 protein selectively inhibits HIV replication and syncytium formation. *Nature*, **1988**, 331, 78-81	50.4	410
2	Analysis of host-virus interactions in AIDS with anti-gp120 T cell clones: effect of HIV sequence variation and a mechanism for CD4+ cell depletion. *Cell*, **1988**, 54, 561-75	56.2	359
1	Activation of cytolytic T lymphocyte and natural killer cell function through the T11 sheep erythrocyte binding protein. *Nature*, **1985**, 317, 428-30	50.4	271